199 related articles for article (PubMed ID: 16934253)
1. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.
Taniguchi Y; Tonai-Kachi H; Shinjo K
FEBS Lett; 2006 Sep; 580(21):5003-8. PubMed ID: 16934253
[TBL] [Abstract][Full Text] [Related]
2. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast.
Cosi C; Mannaioni G; Cozzi A; Carlà V; Sili M; Cavone L; Maratea D; Moroni F
Neuropharmacology; 2011 Jun; 60(7-8):1227-31. PubMed ID: 21110987
[TBL] [Abstract][Full Text] [Related]
3. 5-Nitro-2-(3-phenylpropylamino)benzoic acid is a GPR35 agonist.
Taniguchi Y; Tonai-Kachi H; Shinjo K
Pharmacology; 2008; 82(4):245-9. PubMed ID: 18818509
[TBL] [Abstract][Full Text] [Related]
4. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium.
Yang Y; Lu JY; Wu X; Summer S; Whoriskey J; Saris C; Reagan JD
Pharmacology; 2010; 86(1):1-5. PubMed ID: 20559017
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons.
Guo J; Williams DJ; Puhl HL; Ikeda SR
J Pharmacol Exp Ther; 2008 Jan; 324(1):342-51. PubMed ID: 17940199
[TBL] [Abstract][Full Text] [Related]
6. Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα₁₃ and β-arrestin-2.
Jenkins L; Alvarez-Curto E; Campbell K; de Munnik S; Canals M; Schlyer S; Milligan G
Br J Pharmacol; 2011 Feb; 162(3):733-48. PubMed ID: 20958291
[TBL] [Abstract][Full Text] [Related]
7. Crucial positively charged residues for ligand activation of the GPR35 receptor.
Zhao P; Lane TR; Gao HG; Hurst DP; Kotsikorou E; Le L; Brailoiu E; Reggio PH; Abood ME
J Biol Chem; 2014 Feb; 289(6):3625-38. PubMed ID: 24347166
[TBL] [Abstract][Full Text] [Related]
8. Expression of functional GPR35 in human iNKT cells.
Fallarini S; Magliulo L; Paoletti T; de Lalla C; Lombardi G
Biochem Biophys Res Commun; 2010 Jul; 398(3):420-5. PubMed ID: 20599711
[TBL] [Abstract][Full Text] [Related]
9. GPR35 is a functional receptor in rat dorsal root ganglion neurons.
Ohshiro H; Tonai-Kachi H; Ichikawa K
Biochem Biophys Res Commun; 2008 Jan; 365(2):344-8. PubMed ID: 17996730
[TBL] [Abstract][Full Text] [Related]
10. Kynurenic acid and zaprinast induce analgesia by modulating HCN channels through GPR35 activation.
Resta F; Masi A; Sili M; Laurino A; Moroni F; Mannaioni G
Neuropharmacology; 2016 Sep; 108():136-43. PubMed ID: 27131920
[TBL] [Abstract][Full Text] [Related]
11. Functional G-protein-coupled receptor 35 is expressed by neurons in the CA1 field of the hippocampus.
Alkondon M; Pereira EF; Todd SW; Randall WR; Lane MV; Albuquerque EX
Biochem Pharmacol; 2015 Feb; 93(4):506-18. PubMed ID: 25542997
[TBL] [Abstract][Full Text] [Related]
12. Zaprinast stimulates extracellular adenosine accumulation in rat pontine slices.
Le M; Lu Y; Li Y; Greene RW; Epstein PM; Rosenberg PA
Neurosci Lett; 2004 Nov; 371(1):12-7. PubMed ID: 15500958
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.
Jenkins L; Brea J; Smith NJ; Hudson BD; Reilly G; Bryant NJ; Castro M; Loza MI; Milligan G
Biochem J; 2010 Dec; 432(3):451-9. PubMed ID: 20919992
[TBL] [Abstract][Full Text] [Related]
14. Zaprinast inhibits hydrogen peroxide-induced lysosomal destabilization and cell death in astrocytes.
Choi JH; Kim DH; Yun IJ; Chang JH; Chun BG; Choi SH
Eur J Pharmacol; 2007 Oct; 571(2-3):106-15. PubMed ID: 17643412
[TBL] [Abstract][Full Text] [Related]
15. Structural determinants of phosphodiesterase 6 response on binding catalytic site inhibitors.
Simon A; Barabás P; Kardos J
Neurochem Int; 2006 Aug; 49(3):215-22. PubMed ID: 16519963
[TBL] [Abstract][Full Text] [Related]
16. The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects.
Keswani AN; Peyton KJ; Durante W; Schafer AI; Tulis DA
J Cardiovasc Pharmacol Ther; 2009 Jun; 14(2):116-24. PubMed ID: 19342499
[TBL] [Abstract][Full Text] [Related]
17. Relaxin-3, INSL5, and their receptors.
Liu C; Lovenberg TW
Results Probl Cell Differ; 2008; 46():213-37. PubMed ID: 18236022
[TBL] [Abstract][Full Text] [Related]
18. Light-adaptation attenuates the effects of phosphodiesterase blackade by Zaprinast in the isolated rat retina.
Barabás P; Antal K; Kardos J
Neurosci Lett; 2004 Mar; 357(3):195-8. PubMed ID: 15003283
[TBL] [Abstract][Full Text] [Related]
19. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Giorgi M; D'Angelo V; Esposito Z; Nuccetelli V; Sorge R; Martorana A; Stefani A; Bernardi G; Sancesario G
Eur J Neurosci; 2008 Sep; 28(5):941-50. PubMed ID: 18717735
[TBL] [Abstract][Full Text] [Related]
20. DSM-RX78, a new phosphodiesterase inhibitor, suppresses superoxide anion production in activated human neutrophils and attenuates hemorrhagic shock-induced lung injury in rats.
Yu HP; Hsieh PW; Chang YJ; Chung PJ; Kuo LM; Hwang TL
Biochem Pharmacol; 2009 Oct; 78(8):983-92. PubMed ID: 19540209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
